Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 03:00 save search
Castration-Resistant Prostate Cancer (CRPC) Treatment Market size to grow by USD 5.98 billion from 2023 to 2028, North America to account for 47% of market growth- Technavio
Published: 2024-01-09 (Crawled : 03:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: -3.88%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -0.72%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.46%
H: 0.74%
C: -0.19%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.92%
H: 0.63%
C: -0.25%
america cancer treatment market
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
Published: 2023-12-21 (Crawled : 03:00) - prnewswire.com
CALT | News | $18.3 -2.35% -2.4% 6.1K
|
Health Technology
|
| O: 14.59%
H: 6.13%
C: -1.09%
nefecon nephropathy kidney treatment therapeutics
Retinal Vein Occlusion Treatment Market Size, Share & Trends Analysis Report 2023-2030
Published: 2023-11-15 (Crawled : 03:00) - prnewswire.com
KOD | $3.475 -3.47% -3.6% 570K
|
Health Technology
|
| O: -3.12%
H: 23.12%
C: 8.6%
report treatment trends market
BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS
Published: 2023-09-28 (Crawled : 03:00) - prnewswire.com
BCLI | $0.503 -6.99% -7.51% 1.1M
|
Health Technology
|
| O: -48.44%
H: 6.38%
C: 1.39%
fda als review update cell nurown treatment meeting therapeutics
The Thyroid Gland Disorder Treatment Market to grow by USD 868.87 million from 2022 to 2027 | Abbott Laboratories, AbbVie Inc., Alvogen Iceland ehf, and more among key companies- Technavio
Published: 2023-09-25 (Crawled : 03:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.81%
H: 1.63%
C: -1.03%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.72%
H: 0.0%
C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.21%
H: 1.14%
C: 1.04%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.31%
H: 0.98%
C: 0.97%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.13%
H: 0.91%
C: 0.88%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -1.17%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.06%
H: 0.1%
C: -0.25%
abbvie treatment thyroid market
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
Published: 2023-09-08 (Crawled : 03:00) - globenewswire.com
BNR | $0.7728 -3.4% -3.52% 22K
|
Health Services
|
| O: -4.07%
H: 0.0%
C: -5.08%
lung disease cancer cell results
Advancements in Diagnosis and Treatment Fuel Rising Prevalence of Thalassemia, Driving Market to 2028
Published: 2023-08-25 (Crawled : 03:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.67%
H: 0.45%
C: 0.2%
SGMO | $0.4853 -5.95% -6.33% 1.7M
|
Health Technology
|
| O: -3.19%
H: 0.0%
C: 0.0%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: 1.28%
EDIT | $5.56 -0.89% -0.9% 1.7M
|
Health Technology
|
| O: 0.11%
H: 1.25%
C: -0.57%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.12%
H: 2.12%
C: 1.45%
treatment market
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit
Published: 2023-03-23 (Crawled : 03:00) - globenewswire.com
TNXP | $0.1549 -2.82% -2.91% 1.4M
|
Health Technology
|
| O: 0.24%
H: 3.49%
C: 1.26%
tnx-2900 partnership rare disease innovation treatment pharmaceuticals potential
Water Treatment Systems Global Market Report 2022: Sector to Reach $77.95 Billion by 2030 at an 8.8% CAGR
Published: 2023-03-09 (Crawled : 03:00) - prnewswire.com
ASAN 4 | $13.73 0.07% 2.4% 1.6M
|
Technology Services
|
| O: 12.92%
H: 14.23%
C: 5.32%
water treatment global report market
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
Published: 2023-03-08 (Crawled : 03:00) - novan.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.44%
H: 0.0%
C: -4.26%
molluscum treatment fda pdufa
Global Insecticidal Seed Treatment Strategic Markets Report 2023: Market to Reach $9.2 Billion by 2030 from $4.5 Billion in 2022 - Seed Dressings Market on a Growth Path
Published: 2023-02-22 (Crawled : 03:00) - prnewswire.com
CMP 4 | $13.6 2.03% 0.0% 400K
|
Process Industries
|
| O: -0.15%
H: 2.41%
C: 0.74%
treatment global report growth market
Energy-based non-invasive medical aesthetic treatment system market size is set to grow at a CAGR of 11.11% by 2027, Growth led by Bausch Health Co Inc., Boston Scientific Corp., among others - Technavio
Published: 2023-02-21 (Crawled : 03:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.98%
H: 2.14%
C: 1.46%
treatment system set health medical aesthetic growth market
Fracking water treatment market size to increase by USD 1,208.4 million: Market research insights highlight the increasing consumption of natural gas as a key driver - Technavio
Published: 2023-01-25 (Crawled : 03:00) - prnewswire.com
XYL | $127.16 0.75% 0.0% 1.1M
|
Producer Manufacturing
|
| O: -1.1%
H: 0.59%
C: 0.11%
AQUA | $49.88 0.0% 31M
|
Industrial Services
|
| O: 0.77%
H: 0.0%
C: 0.0%
water treatment research natural market
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Published: 2023-01-09 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: 1.46%
H: 2.22%
C: -2.82%
ath434 treatment system trial therapeutics
Peripheral neuropathy treatment market size to increase by USD 372.56 million: North America to contribute 33% of market growth - Technavio
Published: 2022-12-15 (Crawled : 03:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 620K
|
n/a
|
| O: -3.03%
H: 3.38%
C: -7.75%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.14%
H: 0.4%
C: -1.41%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.53%
H: 0.71%
C: -1.07%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.58%
H: 0.11%
C: -0.41%
america treatment growth market
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Published: 2022-10-13 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: -4.1%
H: 6.41%
C: 6.34%
ath434 treatment system australia trial therapeutics phase 2
Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)
Published: 2022-09-15 (Crawled : 03:00) - prnewswire.com
MNKPF | $17.25
|
n/a
|
| O: 10.71%
H: 16.13%
C: 15.81%
terlivaz treatment fda approval injection
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
Published: 2022-07-14 (Crawled : 03:00) - precisionbiosciences.com
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: -1.96%
H: 2.66%
C: 0.0%
treatment disease collaboration novartis
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
Published: 2022-05-23 (Crawled : 03:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: -1.35%
H: 2.56%
C: -0.34%
xpovio treatment lymphomas
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China
Published: 2022-05-16 (Crawled : 03:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 1.52%
H: 8.99%
C: 2.25%
xpovio treatment commercial china
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.